EDITORIAL

Will oral antithrombin agents replace warfarin?

P R Sinnaeve, F J Van de Werf

The new oral direct thrombin inhibitor ximelagatran is at least equivalent to warfarin for stroke prevention in patients with non-valvar atrial fibrillation, and seems to be a promising adjunct to aspirin after acute coronary syndrome.

Thrombosis, the result of a complex interplay between platelet activation and activation of the coagulation cascade, is a key pathophysiological mechanism in many cardiovascular disorders, including acute coronary syndromes and atrial fibrillation. Atrial fibrillation (AF) is associated with an increased risk of systemic emboli caused by intra-atrial thrombus formation, triggered by mechanical and haemostatic disturbances. In acute coronary syndromes (ACS), plaque rupture exposes von Willebrand factor and collagen, triggering platelet adhesion and activation. The coagulation cascade is also activated by complex formation of tissue factor with activated factor VII. This complex, in turn, leads to activation of factor X and subsequently thrombin formation.

Anticoagulation with warfarin, a vitamin K antagonist, is the mainstay of the prophylactic treatment of stroke and systemic embolic events in most patients with AF. An international normalised ratio (INR) of 2 to 3 is the usual target level of anticoagulation in AF. Inhibiting the coagulation cascade has also been extensively studied in ACS. The benefits of short term treatment after ACS with aspirin and heparin are well known. Nevertheless, there is evidence of a clinically relevant prothrombotic reactivation after cessation of heparin treatment, suggesting that prolonged antithrombin treatment after ACS could be desirable. Indeed, extended administration of high intensity warfarin and moderate intensity warfarin in combination with aspirin also reduces ischaemic complications after ACS.

Until now, vitamin K antagonists, such as warfarin, are the only clinically available oral anticoagulants. Chronic anticoagulation, however, is often cumbersome. Not only does the effect of warfarin differ among patients, it also varies over time in the same individual. Also, various intercurrent illnesses, drugs, and food can influence the level of anticoagulation. Therefore, repeated monitoring of the anticoagulant effect and careful adjustments of warfarin dosage is necessary. In spite of these adjustments oral anticoagulation is associated with an increased risk of bleeding complications. These caveats explain in part why over 40% of patients with AF do not receive anticoagulant treatment, and why physicians are reluctant to give prolonged anticoagulant treatment after ACS.

**ORAL DIRECT THROMBIN INHIBITOR**

The oral direct thrombin inhibitor (DTI) ximelagatran is the first new, clinically tested, oral anticoagulant agent since warfarin was introduced more than 50 years ago. Ximelagatran is rapidly converted to its active metabolite melagatran and is mainly excreted through the kidneys. As an antithrombin, ximelagatran compares favourably with heparin or warfarin. A DTI inhibits thrombin activity better than heparin, and offers better protection against reactivation of thrombin after cessation of treatment. While clot bound thrombin is protected from inactivation by the heparin–antithrombin III complex, it can still be inactivated by DTI. Unlike warfarin, ximelagatran exerts its anticoagulant effect almost immediately, has no known drug or food interactions, and does not require frequent laboratory monitoring. Compared to low molecular weight heparin or warfarin, ximelagatran was shown to be more effective in the prevention of venous thromboembolism after surgery.

Ximelagatran has been evaluated in patients with non-valvar AF with at least one high risk marker (including hypertension, age >75 years, previous stroke, and left ventricular dysfunction). In the SPORTIF III and V trials, ximelagatran was compared with warfarin in the prevention of stroke or systemic thromboembolic complications. In SPORTIF III, 3410 patients with AF and one or more stroke risk factors were randomised to open label, dose adjusted warfarin (target INR 2.0–3.0) or 36 mg ximelagatran twice a day. Ximelagatran was shown to be equivalent to warfarin in terms of stroke prevention, and was associated with a non-significant 29% relative risk reduction of the primary end point of stroke or systemic embolic events. In the recently reported double blind SPORTIF V trial, the same dose of ximelagatran was tested against warfarin in 3922 patients. In the ximelagatran group, patients underwent sham INR testing and dose changes of placebo warfarin. As in SPORTIF III, ximelagatran

**Abbreviations:**

ACS, acute coronary syndrome; AF, atrial fibrillation; DTI, direct thrombin inhibitor; ESTEEM, efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage; INR, international normalised ratio; NSTEMI, non-ST elevated myocardial infarction; SPORTIF, stroke prevention using an oral thrombin inhibitor in patients with atrial fibrillation.
proved to be as effective as warfarin in the prevention of stroke and systemic embolic events.

HIGH RISK ACS PATIENTS

Ximelagatran has also been tested in high risk patients after ACS. Ximelagatran or placebo was given to 1900 patients with a recent ACS in the phase II ESTEEM trial. Patients were included if they had symptoms of ischaemic chest pain in the previous 14 days and at least one additional risk factor (including low ejection fraction, age above 65 years, previous myocardial infarction, congestive heart failure), a raised marker of myocardial damage, and new ischaemic electrocardiographical changes. Of these patients, 66% had an ST elevation myocardial infarction, of whom 50% had received fibrinolytic treatment. They were randomised to aspirin (160 mg) plus placebo or aspirin plus ximelagatran (24–60 mg twice a day). Overall, ximelagatran was associated with a 24% reduction in the composite primary end point of death, myocardial infarction, and recurrent ischaemia (hazard ratio (HR) 0.76, 95% confidence interval (CI) 0.59 to 0.98, p = 0.036). No dose response was observed. In a post-hoc analysis, the “thrombotic” end point of death, non-fatal myocardial infarction, and stroke was reduced by 34% (HR 0.66, 95% CI 0.48 to 0.90) in the total patient group allocated to the ximelagatran group. This effect was seen early on, and the Kaplan-Meier event curves tended to diverge further after 30 days, suggesting a continuing effect.

SAFETY

Is ximelagatran a perfectly safe alternative for warfarin? Unfortunately, ximelagatran induces liver enzyme elevations with serum transaminases higher than three times the upper limit within the first 2–6 months in about 6–10% of patients. Although enzyme elevations generally seem to be benign and tend to resolve spontaneously or after drug withdrawal, monitoring of liver enzymes will probably be required during the first six months after treatment initiation. Furthermore, in the SPORTIF III and V trials, major bleeding complications were not significantly different in both treatment arms. In this respect, it is not unlikely that clinicians might also be reluctant to start ximelagatran in patients considered to be at high risk for bleeding complications with warfarin. On the other hand, the significantly lower rate of minor bleeding complications observed in the SPORTIF trials and the lack of drug or food interactions make ximelagatran a promising alternative for warfarin. Currently, regulatory approval is being sought for ximelagatran.

In the meantime, other oral antithrombin agents are being investigated in preclinical studies. Alternative anticoagulant strategies including oral heparin formulations and orally active direct anti-Xa agents are also currently being developed. Agents that inhibit activated factor X are highly potent and orally bioavailable pyrazole antithrombotic agent. Moreover, the role and safety of ximelagatran in combination with contemporary antiplatelet regimens (clopidogrel and aspirin) remains to be determined.

Authors’ affiliations

P R Sinnaeve, F J Van de Werf, Department of Cardiology, University of Leuven, Leuven, Belgium

REFERENCE